Clinical Trial Update: Disrupt CAD III Post-Approval Study (PAS)

View source ↗

Summary

Post-approval study update for Disrupt CAD III; completed with results posted in February 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Infarction

Drugs mentioned

• Disrupt CAD III

Snippet

Sponsor: Shockwave Medical, Inc. | Conditions: Coronary Artery Disease, Myocardial Infarction | Status: COMPLETED | Results posted: 2024-02-01